New Bipartisan Bill Aims to Cap Insulin Costs at $35 Monthly

A new bipartisan bill in the U.S. seeks to limit insulin costs for millions of Americans who rely on the life-saving drug. The INSULIN Act would cap monthly expenses at $35 for those with private insurance. Without action, many patients—including over 2 million with Type 1 diabetes—face steep and unpredictable pricing.

Currently, more than 8.1 million people in the country depend on insulin, yet prices remain volatile. Some families pay hundreds of dollars each month, even as major manufacturers like Eli Lilly, Sanofi, and Novo Nordisk have begun reducing costs in recent years.

The INSULIN Act was introduced by Sens. Jeanne Shaheen, Raphael Warnock, Susan Collins, and John Kennedy. If passed, it would enforce a $35 monthly cap for privately insured patients. The bill also proposes a pilot program to help uninsured Americans access cheaper insulin in 10 states.

Insulin affordability has become a pressing issue, with costs varying widely across the U.S. Last week, the parents of a Mississippi toddler with diabetes paid $194 for a one-month supply of vials and a three-month backup of insulin pens. His mother, Marlee Brandon, fears these expenses will only rise as her son grows older. Over half of U.S. states have already set their own insulin co-pay limits, ranging from $25 to $100 per month. Colorado and New York cap costs at $35, while California sets the limit at $50. Despite these efforts, gaps remain for those without state-regulated insurance or who fall outside existing protections. The INSULIN Act still faces challenges, including debates over funding and competition with other congressional priorities. While drugmakers have lowered some prices, not all patients benefit from these changes, leaving many struggling with high out-of-pocket costs.

The bill's success would directly affect millions, particularly those with Type 1 diabetes who cannot survive without insulin. If approved, the $35 cap would bring consistency to pricing for privately insured patients. Meanwhile, the proposed pilot program could extend relief to uninsured individuals in select states.